{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:04:09Z","timestamp":1777518249320,"version":"3.51.4"},"reference-count":30,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:00:00Z","timestamp":1569196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Therapeutic drug monitoring is routinely performed to maintain optimal tacrolimus concentrations in kidney transplant recipients. Nonetheless, toxicity and rejection still occur within an acceptable concentration-range. To have a better understanding of the relationship between tacrolimus dose, tacrolimus concentration, and its effect on the target cell, we developed functional immune tests for the quantification of the tacrolimus effect. Twelve healthy volunteers received a single dose of tacrolimus, after which intracellular and whole blood tacrolimus concentrations were measured and were related to T cell functionality. A significant correlation was found between tacrolimus concentrations in T cells and whole blood concentrations (r = 0.71, p = 0.009), while no correlation was found between tacrolimus concentrations in peripheral blood mononuclear cells (PBMCs) and whole blood (r = 0.35, p = 0.27). Phytohemagglutinin (PHA) induced the production of IL-2 and IFN\u03b3, as well as the inhibition of CD71 and CD154 expression on T cells at 1.5 h post-dose, when maximum tacrolimus levels were observed. Moreover, the in vitro tacrolimus effect of the mentioned markers corresponded with the ex vivo effect after dosing. In conclusion, our results showed that intracellular tacrolimus concentrations mimic whole blood concentrations, and that PHA-induced cytokine production (IL-2 and IFN\u03b3) and activation marker expression (CD71 and CD154) are suitable readout measures to measure the immunosuppressive effect of tacrolimus on the T cell.<\/jats:p>","DOI":"10.3390\/ijms20194710","type":"journal-article","created":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T11:02:00Z","timestamp":1569236520000},"page":"4710","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunomonitoring of Tacrolimus in Healthy Volunteers: The First Step from PK- to PD-Based Therapeutic Drug Monitoring?"],"prefix":"10.3390","volume":"20","author":[{"given":"Aliede E.","family":"in \u2018t Veld","sequence":"first","affiliation":[{"name":"Centre for Human Drug Research, 2333 CL, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5611-108X","authenticated-orcid":false,"given":"Hendrika W.","family":"Grievink","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, 2333 CL, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdi","family":"Saghari","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, 2333 CL, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0013-8355","authenticated-orcid":false,"given":"Frederik E.","family":"Stuurman","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, 2333 CL, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke L.","family":"de Kam","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, 2333 CL, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiko P. J.","family":"de Vries","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda C. M.","family":"de Winter","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus Medical Center, 3014 GD, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacobus","family":"Burggraaf","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, 2333 CL, Leiden, The Netherlands"},{"name":"Division of Pharmacology, Leiden Academic Centre for Drug Research, 2333 CC, Leiden, The Netherlands"},{"name":"Department of Surgery, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam F.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, 2333 CL, Leiden, The Netherlands"},{"name":"Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthijs","family":"Moerland","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, 2333 CL, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.kint.2018.05.018","article-title":"Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015","volume":"94","author":"Coemans","year":"2018","journal-title":"Kidney Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/TP.0b013e3182708ea8","article-title":"Kidney graft survival in Europe and the United States: Strikingly different long-term outcomes","volume":"95","author":"Gondos","year":"2013","journal-title":"Transplantation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","article-title":"Intra-patient variability in tacrolimus exposure: Causes, consequences for clinical management","volume":"29","author":"Shuker","year":"2015","journal-title":"Transplant. Rev. (Orlando)"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/17425255.2017.1395413","article-title":"Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients","volume":"13","author":"Andrews","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/ajt.12191","article-title":"Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: A pooled analysis from three randomized-controlled clinical trials(dagger)","volume":"13","author":"Bouamar","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/FTD.0000000000000539","article-title":"Longitudinal Study of Tacrolimus in Lymphocytes During the First Year After Kidney Transplantation","volume":"40","author":"Klaasen","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","article-title":"Mode of action of tacrolimus (FK506): Molecular and cellular mechanisms","volume":"17","author":"Thomson","year":"1995","journal-title":"Ther. Drug Monit."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1373\/clinchem.2014.223511","article-title":"Tacrolimus pharmacodynamics and pharmacogenetics along the calcineurin pathway in human lymphocytes","volume":"60","author":"Noceti","year":"2014","journal-title":"Clin. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3727\/000000001783986387","article-title":"Inhibition of cytokine production and cytokine-stimulated T-cell activation by FK506 (tacrolimus)1","volume":"10","author":"Almawi","year":"2001","journal-title":"Cell Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1373\/clinchem.2003.024950","article-title":"Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): Impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect","volume":"50","author":"Hartel","year":"2004","journal-title":"Clin. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kannegieter, N.M., Hesselink, D.A., Dieterich, M., de Graav, G.N., Kraaijeveld, R., and Baan, C.C. (2018). Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0201113"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5414\/CN108893","article-title":"Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients","volume":"87","author":"Keller","year":"2017","journal-title":"Clin. Nephrol."},{"key":"ref_13","first-page":"462","article-title":"Phytohemagglutinin: An initiator of mitosis in cultures of normal human leukocytes","volume":"20","author":"Nowell","year":"1960","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ab.2006.08.013","article-title":"Spectrophotometric assay for calcineurin activity in leukocytes isolated from human blood","volume":"358","author":"Sellar","year":"2006","journal-title":"Anal. Biochem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FTD.0b013e318198d092","article-title":"Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European consensus conference","volume":"31","author":"Wallemacq","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0091270003261078","article-title":"Effects of St. John\u2019s wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers","volume":"44","author":"Hebert","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/cyto.a.20859","article-title":"Evaluation of a 12-color flow cytometry panel to study lymphocyte, monocyte, and dendritic cell subsets in humans","volume":"77","author":"Autissier","year":"2010","journal-title":"Cytometry A."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1097\/TXD.0000000000000715","article-title":"The Effects of Tacrolimus on T-Cell Proliferation Are Short-Lived: A Pilot Analysis of Immune Function Testing","volume":"3","author":"Laskin","year":"2017","journal-title":"Transplant. Direct"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e4416","DOI":"10.1002\/bmc.4416","article-title":"Highly sensitive and rapid determination of tacrolimus in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry","volume":"33","author":"Bahmany","year":"2019","journal-title":"Biomed. Chromatogr."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Han, S.S., Yang, S.H., Kim, M.C., Cho, J.Y., Min, S.I., Lee, J.P., Kim, D.K., Ha, J., and Kim, Y.S. (2016). Monitoring the Intracellular Tacrolimus Concentration in Kidney Transplant Recipients with Stable Graft Function. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153491"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.clinbiochem.2014.12.018","article-title":"Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: Inside the white blood cells","volume":"48","author":"Lemaitre","year":"2015","journal-title":"Clin. Biochem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1432-2277.2011.01365.x","article-title":"Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: Preliminary results of a prospective study","volume":"25","author":"Capron","year":"2012","journal-title":"Transplant. Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.clinbiochem.2015.07.099","article-title":"Lymphocyte surface molecules as immune activation biomarkers","volume":"49","author":"Wieland","year":"2016","journal-title":"Clin. Biochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/00007890-199805150-00018","article-title":"T-cell and monocyte subsets, inflammatory molecules, rejection, and hemodynamics early after cardiac transplantation","volume":"65","author":"Deng","year":"1998","journal-title":"Transplantation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0009-8981(02)00045-1","article-title":"Diagnostic value of peripheral blood T-cell activation and soluble IL-2 receptor for acute rejection in liver transplantation","volume":"320","author":"Lun","year":"2002","journal-title":"Clin. Chim. Acta"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/TP.0b013e318225276d","article-title":"Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation","volume":"92","author":"Ashokkumar","year":"2011","journal-title":"Transplantation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00228-005-0933-6","article-title":"Population pharmacokinetics of tacrolimus in full liver transplant patients: Modelling of the post-operative clearance","volume":"61","author":"Antignac","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/FTD.0b013e31829f1ab8","article-title":"Population pharmacokinetics of tacrolimus in adult kidney transplant patients: Impact of CYP3A5 genotype on starting dose","volume":"36","author":"Bergmann","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/FTD.0000000000000134","article-title":"Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients","volume":"37","author":"Andreu","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1067\/mcp.2002.129304","article-title":"Population pharmacokinetics of tacrolimus in adult kidney transplant recipients","volume":"72","author":"Staatz","year":"2002","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/19\/4710\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:23:13Z","timestamp":1760188993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/19\/4710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,23]]},"references-count":30,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["ijms20194710"],"URL":"https:\/\/doi.org\/10.3390\/ijms20194710","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,23]]}}}